Revenue

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

A landmark clinical trial shows umbilical cord blood can safely reduce debilitating back pain, opening a new frontier beyond traditional stem cell uses.

Japanese auto software firm Micware hits Nasdaq, raising $22.8M to power next-gen vehicle tech and challenge the industry's global giants.

Crescent BDC announced shareholder-friendly moves but reported a significant net loss and declining asset value, painting a complex picture for investors.

Amid industry-wide price pressure, MariMed reports revenue growth and improved profitability, bolstered by savvy debt restructuring and brand expansion.

Malaysian aquaculture firm Megan Holdings' stock has plummeted, triggering a Nasdaq delisting warning and a six-month race to regain compliance.

METiS TechBio's stock surged over 170% on its debut, as investors bet big on its AI-powered platform to build the future of precision drug delivery.

Industrial AI leader showcases autonomous factory solutions in Kuala Lumpur, aligning with Malaysia's strategy to capture a larger slice of the global chip market.

New Pacific Metals reports a Q3 net loss but holds a strong $39M in capital, securing a crucial community agreement for its Carangas project in Bolivia.

NEC showcases a suite of AI solutions at NRF 2026 APAC, tackling everything from operational efficiency and lost sales to critical cybersecurity threats.

Insurtech leader Ethos releases a significant block of shares, providing liquidity to early backers and setting up a major test for the stock and the sector.

With 799% revenue growth and major Fortune 10 deals, Energous proves wireless power is no longer a gadget gimmick but essential industrial tech.

The insurtech's capital-light model shines with soaring revenue and adjusted profits, proving the power of its Risk Exchange despite a reported net loss.

The 2026 Chandler Index reveals a paradox: government performance is up, but a staggering 70% of nations are fiscally weaker than five years ago.

With strong HIFU revenue and new clinical trials, EDAP TMS's upcoming Investor Day will reveal its strategy for medtech dominance and investor confidence.

As the space economy booms, a top TMT research firm launches dedicated coverage, signaling a new era of financial scrutiny for giants like SpaceX and Rocket Lab.

Online firearms retailer GrabAGun reports strong sales growth, but strategic spending on new ventures and infrastructure leads to a Q1 net loss.

After years of economic collapse, Venezuela launches a massive debt restructuring. Can it untangle a web of creditors and legal battles to forge a recovery?

AutoCanada posts a Q1 loss amid a soft market, accelerating its U.S. dealership sale and relying on new leadership and its collision arm for recovery.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.